Company intelligence

BLRX

BioLineRx Ltd. · NASDAQ · Healthcare

Price$2.60-5.63% · −$0.16

Market cap11.31MEquity value

P / E-1.4Trailing ratio

Volume47.84KLatest session

Market data

BLRX price chart

TradingView

Related signals

1 min delayed

Browse public BLRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BLRXMay 30, 2025-24.61% since signal

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BLRX's Phase 2 trial shows promising results in pancreatic cancer treatment. Pilot study demonstrates a 64% overall response rate using motixafortide combination. Funding secured with a $10 million raise, extending the cash runway. Company plans to significantly reduce operating expenses starting early 2025. Jones Trading upgrades BLRX to 'Buy' with a $12 price target.

View signal analysis

BLRXJan 6, 20250.00% since signal

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

U.S. stocks rose, Nasdaq gained over 200 points. BLRX fell 42% due to direct offering. S&P Global services PMI revised to 56.8, affecting market sentiment. Poor economic indicators influence biotech stocks. Utilities shares dropped 0.6% while tech surged 2.1%. Market performance indicates sector rotation risk.

View signal analysis

Research